加强雄激素剥夺治疗(ADT)在前列腺癌中的整合:立体定向体部放疗(SBRT)与近距离治疗(BT)模式的启示
本文讨论雄激素剥夺治疗(ADT)联合立体定向体部放疗(SBRT)和近距离治疗(BT)推量治疗前列腺癌的争议与临床实践演变。现有证据提示省略ADT可能导致肿瘤学结局较差。推荐对不利中危和高危患者放疗时启动ADT,不利中危至少6个月、高危至少12个月,并强调个体化决策。
要点
- 不利中危前列腺癌患者接受放疗时推荐启动ADT,最短疗程6个月。
- 高危前列腺癌患者接受放疗时推荐启动ADT,最短疗程至少12个月。
- ADT整合决策应个体化,兼顾肿瘤学结局与副作用最小化。
核心结论
- 推荐对接受放疗的不利中危和高危前列腺癌患者启动ADT,不利中危最短6个月、高危至少12个月,决策应个体化。
研究设计与样本
- 本文为综述,讨论ADT联合SBRT和BT推量治疗前列腺癌的临床实践与证据。
主要发现
- 当代趋势倾向于在SBRT和BT中ADT使用不足,但现有证据提示省略ADT可能导致肿瘤学结局较差。
- 正在进行的PACE-C、SPA、SHIP 0804和SHIP 36B等临床试验有望提供ADT最佳用法与疗程的见解。
关键数值与推荐
- 推荐对接受放疗的不利中危和高危前列腺癌患者启动ADT,不利中危最短6个月,高危至少12个月。
- ADT推荐应基于患者个体风险特征和合并症,以最佳肿瘤学结局并最小化副作用为目标。
临床怎么用
- 对接受SBRT或BT的不利中危和高危前列腺癌患者,按上述最短疗程启动ADT,并结合个体风险与合并症进行个体化决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost in prostate cancer treatment is a subject of ongoing debate and evolving clinical practice. While contemporary trends lean towards underutilizing ADT with these modalities, existing evidence suggests that its omission may lead to potentially inferior oncologic outcomes. Recommendations for ADT use should be patient-centric, considering individual risk profiles and comorbidities, with a focus on achieving optimal oncologic outcomes while minimizing potential side effects. Ongoing clinical trials, such as PACE-C, SPA, SHIP 0804, and SHIP 36B, are anticipated to provide valuable insights into the optimal use and duration of ADT in both SBRT and BT settings. Until new evidence emerges, it is recommended to initiate ADT for unfavorable intermediate-risk and high-risk prostate cancer patients undergoing radiotherapy, with a minimum duration of 6 months for unfavorable intermediate-risk patients and at least 12 months for those with high-risk characteristics. The decision to incorporate ADT into these radiation therapy modalities should be individualized, acknowledging the unique needs of each patient and emphasizing a tailored approach to achieve the best possible oncologic outcomes.
引用
- Gomez-Iturriaga A, Büchser D, Lopez-Campos F, et al. Enhancing Androgen Deprivation Therapy (ADT) integration in prostate cancer: Insights for Stereotactic Body Radiotherapy (SBRT) and brachytherapy modalities. Clin Transl Radiat Oncol. 2024. PMID: 38322544. doi:10.1016/j.ctro.2024.100733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。